<DOC>
	<DOCNO>NCT01473251</DOCNO>
	<brief_summary>The purpose study measure biomarkers vitreous patient undergo Lucentis avastin treatment .</brief_summary>
	<brief_title>Analysis Growth Factors Patients Undergoing Lucentis Avastin Injections Diabetic Macular Edema Exudative Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Male female age 18 85 diabetes hemoglobin A1C &lt; /= 10 , exudative macular degeneration . Diabetic macular edema average retinal thickness central subfield &gt; /= 290um . Macular atrophy/fibrosis . Ocular antiVEGF treatment within 3 month . Treatment topical oral carbonicanhydrase inhibitor within one month Laser photocoagulation within 3 month ( diabetic cohort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>